{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:00:27Z","timestamp":1763748027769,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81202071"],"award-info":[{"award-number":["81202071"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-6087-1","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T08:04:13Z","timestamp":1567670653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Inhibitory short peptides targeting EPS8\/ABI1\/SOS1 tri-complex suppress invasion and metastasis of ovarian cancer cells"],"prefix":"10.1186","volume":"19","author":[{"given":"Xuechen","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8444-7157","authenticated-orcid":false,"given":"Huijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"issue":"1","key":"6087_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9\u201329. https:\/\/doi.org\/10.3322\/caac.21208 .","journal-title":"CA Cancer J Clin"},{"issue":"Supplement_4","key":"6087_CR2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdy001","volume":"29","author":"I Ray-Coquard","year":"2018","unstructured":"Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, et al. ESMO Guidelines Committee. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement_4):iv1\u2013iv18. https:\/\/doi.org\/10.1093\/annonc\/mdy001 .","journal-title":"Ann Oncol"},{"issue":"5B","key":"6087_CR3","first-page":"3135","volume":"28","author":"M Argento","year":"2008","unstructured":"Argento M, Hoffman P, Gauchez AS. Ovarian cancer detection and treatment: current situation and future prospects. Anticancer Res. 2008;28(5B):3135\u20138.","journal-title":"Anticancer Res"},{"issue":"10","key":"6087_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrc3144","volume":"11","author":"S Vaughan","year":"2011","unstructured":"Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11(10):719\u201325. https:\/\/doi.org\/10.1038\/nrc3144 .","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"6087_CR5","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1200\/JCO.2006.07.9970","volume":"26","author":"CN Landen Jr","year":"2008","unstructured":"Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008;26(6):995\u20131005. https:\/\/doi.org\/10.1200\/JCO.2006.07.9970 .","journal-title":"J Clin Oncol"},{"issue":"3","key":"6087_CR6","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053\u201364. https:\/\/doi.org\/10.2353\/ajpath.2010.100105 .","journal-title":"Am J Pathol"},{"issue":"6","key":"6087_CR7","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3109\/10799893.2015.1026444","volume":"35","author":"A Jesionowska","year":"2015","unstructured":"Jesionowska A, Cecerska-Heryc E, Matoszka N, Dolegowska B. Lysophosphatidic acid signaling in ovarian cancer. J Recept Signal Transduct Res. 2015;35(6):578\u201384. https:\/\/doi.org\/10.3109\/10799893.2015.1026444 .","journal-title":"J Recept Signal Transduct Res"},{"issue":"10","key":"6087_CR8","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.2217\/fon.09.120","volume":"5","author":"TL Pua","year":"2009","unstructured":"Pua TL, Wang FQ, Fishman DA. Roles of LPA in ovarian cancer development and progression. Future Oncol. 2009;5(10):1659\u201373. https:\/\/doi.org\/10.2217\/fon.09.120 .","journal-title":"Future Oncol"},{"issue":"1\u20133","key":"6087_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1388-1981(02)00179-8","volume":"1582","author":"X Fang","year":"2002","unstructured":"Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta. 2002;1582(1\u20133):257\u201364.","journal-title":"Biochim Biophys Acta"},{"issue":"16","key":"6087_CR10","doi-asserted-by":"publisher","first-page":"7983","DOI":"10.1158\/0008-5472.CAN-05-4381","volume":"66","author":"KS Kim","year":"2006","unstructured":"Kim KS, Sengupta S, Berk M, Kwak YG, Escobar PF, Xu Y, et al. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells andlysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res. 2006;66(16):7983\u201390.","journal-title":"Cancer Res"},{"issue":"22","key":"6087_CR11","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/jnci\/djn378","volume":"100","author":"S Yu","year":"2008","unstructured":"Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, et al. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst. 2008;100(22):1630\u201342. https:\/\/doi.org\/10.1093\/jnci\/djn378 .","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"6087_CR12","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.ygyno.2006.10.016","volume":"104","author":"P Wang","year":"2007","unstructured":"Wang P, Wu X, Chen W, Liu J, Wang X. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Gynecol Oncol. 2007;104(3):714\u201320.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"6087_CR13","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1186\/s12885-016-2865-1","volume":"16","author":"X Yu","year":"2016","unstructured":"Yu X, Zhang Y, Chen H. LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study. BMC Cancer. 2016;16(1):846.","journal-title":"BMC Cancer"},{"issue":"23","key":"6087_CR14","doi-asserted-by":"publisher","first-page":"9979","DOI":"10.1158\/0008-5472","volume":"70","author":"H Chen","year":"2010","unstructured":"Chen H, Wu X, Pan ZK, Huang S. Integrity of SOS1\/EPS8\/ABI1 tri-complex determines ovarian cancer metastasis. Cancer Res. 2010;70(23):9979\u201390. https:\/\/doi.org\/10.1158\/0008-5472 .","journal-title":"Cancer Res"},{"issue":"9","key":"6087_CR15","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.bcp.2011.07.072","volume":"82","author":"S Pierre","year":"2011","unstructured":"Pierre S, Bats AS, Coumoul X. Understanding SOS (son of Sevenless). Biochem Pharmacol. 2011;82(9):1049\u201356. https:\/\/doi.org\/10.1016\/j.bcp.2011.07.072 .","journal-title":"Biochem Pharmacol"},{"issue":"13","key":"6087_CR16","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1101\/gad.1003302","volume":"16","author":"A Schmidt","year":"2002","unstructured":"Schmidt A, Hall A. Guanine nucleotide exchange factors for rho GTPases: turning on the switch. Genes Dev. 2002;16(13):1587\u2013609.","journal-title":"Genes Dev"},{"issue":"1","key":"6087_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1083\/jcb.200108035","volume":"156","author":"M Innocenti","year":"2002","unstructured":"Innocenti M, Tenca P, Frittoli E, Faretta M, Tocchetti A, Di Fiore PP, et al. Mechanisms through which Sos-1 coordinates the activation of Ras and Rac. J Cell Biol. 2002;156(1):125\u201336.","journal-title":"J Cell Biol"},{"issue":"1","key":"6087_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1083\/jcb.200206079","volume":"160","author":"M Innocenti","year":"2003","unstructured":"Innocenti M, Frittoli E, Ponzanelli I, Falck JR, Brachmann SM, Di Fiore PP, et al. Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1. J Cell Biol. 2003;160(1):17\u201323.","journal-title":"J Cell Biol"},{"issue":"17","key":"6087_CR19","doi-asserted-by":"publisher","first-page":"15287","DOI":"10.1074\/jbc.M109.094441","volume":"286","author":"Shreya Mitra","year":"2011","unstructured":"Mitra S, Lee JS, Cantrell M, Van den Berg CL. C-Jun N-terminal kinase 2 (JNK2) enhances cell migration through epidermal growth factor substrate 8 (EPS8). J Biol Chem. 2011;286(17):15287\u201397. https:\/\/doi.org\/10.1074\/jbc.M109.094441 .","journal-title":"Journal of Biological Chemistry"},{"issue":"6750","key":"6087_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/45822","volume":"401","author":"G Scita","year":"1999","unstructured":"Scita G, Nordstrom J, Carbone R, Tenca P, Giardina G, Gutkind S, et al. EPS8 and E3B1 transduce signals from Ras to Rac. Nature. 1999;401(6750):290\u20133.","journal-title":"Nature."},{"issue":"10","key":"6087_CR21","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S1357-2725(02)00064-X","volume":"34","author":"PP Di Fiore","year":"2002","unstructured":"Di Fiore PP, Scita G. Eps8 in the midst of GTPases. Int J Biochem Cell Biol. 2002;34(10):1178\u201383.","journal-title":"Int J Biochem Cell Biol"},{"issue":"5","key":"6087_CR22","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1083\/jcb.200103146","volume":"154","author":"G Scita","year":"2001","unstructured":"Scita G, Tenca P, Areces LB, Tocchetti A, Frittoli E, Giardina G, et al. An effector region in Eps8 is responsible for the activation of the Rac-specific GEF activity of Sos-1 and for the proper localization of the Rac-based actin-polymerizing machine. J Cell Biol. 2001;154(5):1031\u201344.","journal-title":"J Cell Biol"},{"issue":"10","key":"6087_CR23","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.2217\/fon.13.104","volume":"9","author":"YH Li","year":"2013","unstructured":"Li YH, Xue TY, He YZ, Du JW. Novel oncoprotein EPS8: a new target for anticancer therapy. Future Oncol. 2013;9(10):1587\u201394. https:\/\/doi.org\/10.2217\/fon.13.104 .","journal-title":"Future Oncol"},{"issue":"17","key":"6087_CR24","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/j.febslet.2012.05.015","volume":"586","author":"L Kotula","year":"2012","unstructured":"Kotula L. Abi1, a critical molecule coordinating actin cytoskeleton reorganization with PI-3 kinase and growth signaling. FEBS Lett. 2012;586(17):2790\u20134. https:\/\/doi.org\/10.1016\/j.febslet.2012.05.015 .","journal-title":"FEBS Lett"},{"issue":"20","key":"6087_CR25","doi-asserted-by":"publisher","first-page":"7591","DOI":"10.1128\/MCB.20.20.7591-7601.2000","volume":"20","author":"PD Fan","year":"2000","unstructured":"Fan PD, Goff SP. Abl interactor 1 binds to sos and inhibits epidermal growth factor- and v-Abl-induced activation of extracellular signal-regulated kinases. Mol Cell Biol. 2000;20(20):7591\u2013601.","journal-title":"Mol Cell Biol"},{"issue":"19","key":"6087_CR26","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1093\/emboj\/18.19.5300","volume":"18","author":"AM Mongiov\u00ed","year":"1999","unstructured":"Mongiov\u00ed AM, Romano PR, Panni S, Mendoza M, Wong WT, Musacchio A, et al. A novel peptide-SH3 interaction. EMBO J. 1999;18(19):5300\u20139.","journal-title":"EMBO J"},{"issue":"12","key":"6087_CR27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/cbin.10841","volume":"41","author":"M Ahram","year":"2017","unstructured":"Ahram M, Mustafa E, Zaza R, Abu Hammad S, Alhudhud M, Bawadi R, et al. Differential expression and androgen regulation of microRNAs and metalloprotease 13 in breast cancer cells. Cell Biol Int. 2017;41(12):1345\u201355. https:\/\/doi.org\/10.1002\/cbin.10841 .","journal-title":"Cell Biol Int"},{"issue":"1","key":"6087_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41391-018-0035-z","volume":"21","author":"B Benzon","year":"2018","unstructured":"Benzon B, Glavaris SA, Simons BW, Hughes RM, Ghabili K, Mullane P. Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer. Prostate Cancer Prostatic Dis. 2018;21(1):126\u201336. https:\/\/doi.org\/10.1038\/s41391-018-0035-z .","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"6087_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.bbamem.2016.08.013","volume":"1859","author":"TA Stone","year":"2017","unstructured":"Stone TA, Deber CM. Therapeutic design of peptide modulators of protein-protein interactions in membranes. Biochim Biophys Acta Biomembr. 2017;1859(4):577\u201385. https:\/\/doi.org\/10.1016\/j.bbamem.2016.08.013 .","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"3","key":"6087_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2174\/156802611794072632","volume":"11","author":"LM Meireles","year":"2011","unstructured":"Meireles LM, Mustata G. Discovery of modulators of protein-protein interactions: current approaches and limitations. Curr Top Med Chem. 2011;11(3):248\u201357.","journal-title":"Curr Top Med Chem"},{"key":"6087_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.sbi.2016.12.009","volume":"44","author":"AD Cunningham","year":"2017","unstructured":"Cunningham AD, Qvit N, Mochly-Rosen D. Peptides and peptidomimetics as regulators of protein-protein interactions. Curr Opin Struct Biol. 2017;44:59\u201366. https:\/\/doi.org\/10.1016\/j.sbi.2016.12.009 .","journal-title":"Curr Opin Struct Biol"},{"key":"6087_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-3-319-32805-8_8","volume":"917","author":"D Helmer","year":"2016","unstructured":"Helmer D, Schmitz K. Peptides and peptide analogs to inhibit protein-protein interactions. Adv Exp Med Biol. 2016;917:147\u201383. https:\/\/doi.org\/10.1007\/978-3-319-32805-8_8 .","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"6087_CR33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","volume":"20","author":"K Fosgerau","year":"2015","unstructured":"Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122\u20138. https:\/\/doi.org\/10.1016\/j.drudis.2014.10.003 .","journal-title":"Drug Discov Today"},{"issue":"2","key":"6087_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4155\/fmc-2016-0189","volume":"9","author":"A llert-Miklaszewska","year":"2017","unstructured":"llert-Miklaszewska A, Poleszak K, Kaminska B. Short peptides interfering with signaling pathways as new therapeutic tools for cancer treatment. Future Med Chem. 2017;9(2):199\u2013221. https:\/\/doi.org\/10.4155\/fmc-2016-0189 .","journal-title":"Future Med Chem"},{"issue":"7","key":"6087_CR35","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1158\/1078-0432.CCR-04-1564","volume":"11","author":"DG Bae","year":"2005","unstructured":"Bae DG, Kim TD, Li G, Yoon WH, Chae CB. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis. Clin Cancer Res. 2005;11(7):2651\u201361.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"6087_CR36","doi-asserted-by":"publisher","first-page":"12266","DOI":"10.1074\/jbc.275.16.12266","volume":"275","author":"S Huang","year":"2000","unstructured":"Huang S, New L, Pan Z, Han J, Nemerow GR. Urokinase plasminogen activator\/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity. J Biol Chem. 2000;275(16):12266\u201372.","journal-title":"J Biol Chem"},{"issue":"6","key":"6087_CR37","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ymthe.2004.08.013","volume":"10","author":"TJ Shaw","year":"2004","unstructured":"Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther. 2004;10(6):1032\u201342.","journal-title":"Mol Ther"},{"issue":"11","key":"6087_CR38","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S0960-9822(01)00239-1","volume":"11","author":"T Stradal","year":"2001","unstructured":"Stradal T, Courtney KD, Rottner K, Hahne P, Small JV, Pendergast AM. The Abl interactor proteins localize to sites of actin polymerization at the tips of lamellipodia and filopodia. Curr Biol. 2001;11(11):891\u20135.","journal-title":"Curr Biol"},{"issue":"4","key":"6087_CR39","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1073\/pnas.0409120102","volume":"102","author":"Y Leng","year":"2005","unstructured":"Leng Y, Zhang J, Badour K, Arpaia E, Freeman S, Cheung P, et al. Abelson-interactor-1 promotes WAVE2 membrane translocation and Abelson-mediated tyrosine phosphorylation required for WAVE2 activation. Proc Natl Acad Sci U S A. 2005;102(4):1098\u2013103.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"6087_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/ncb1105","volume":"6","author":"M Innocenti","year":"2004","unstructured":"Innocenti M, Zucconi A, Disanza A, Frittoli E, Areces LB, Steffen A, et al. Abi1 is essential for the formation and activation of a WAVE2 signalling complex. Nat Cell Biol. 2004;6(4):319\u201327.","journal-title":"Nat Cell Biol"},{"issue":"11","key":"6087_CR41","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1128\/MCB.24.11.4979-4993.2004","volume":"24","author":"K Tani","year":"2004","unstructured":"Tani K, Sato S, Sukezane T, Kojima H, Hirose H, Hanafusa H, et al. Abl interactor 1 promotes tyrosine 296 phosphorylation of mammalian enabled (Mena) by c-Abl kinase. J Biol Chem. 2003 Jun 13; 278(24):21685-92. Mol Cell Biol. 2004;24(11):4979\u201393.","journal-title":"Mol Cell Biol"},{"issue":"11","key":"6087_CR42","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1128\/MCB.24.11.4979-4993.2004","volume":"24","author":"A Echarri","year":"2004","unstructured":"Echarri A, Lai MJ, Robinson MR, Pendergast AM. Abl interactor 1 (Abi-1) wave-binding and SNARE domains regulate its nucleocytoplasmic shuttling, lamellipodium localization, and wave-1 levels. Mol Cell Biol. 2004;24(11):4979\u201393.","journal-title":"Mol Cell Biol"},{"issue":"145","key":"6087_CR43","doi-asserted-by":"crossref","first-page":"pe36","DOI":"10.1126\/stke.2002.145.pe36","volume":"2002","author":"A Nimnual","year":"2002","unstructured":"Nimnual A, Bar-Sagi D. The two hats of SOS. Sci STKE. 2002;2002(145):pe36.","journal-title":"Sci STKE"},{"key":"6087_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12964-015-0119-5","volume":"13","author":"S Sekino","year":"2015","unstructured":"Sekino S, Kashiwagi Y, Kanazawa H, Takada K, Baba T, Sato S, et al. The NESH\/Abi-3-based WAVE2 complex is functionally distinct from the Abi-1-based WAVE2 complex. Cell Commun Signal. 2015;13:41. https:\/\/doi.org\/10.1186\/s12964-015-0119-5 .","journal-title":"Cell Commun Signal"},{"issue":"3","key":"6087_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/ncb0304-189","volume":"6","author":"A Joliot","year":"2004","unstructured":"Joliot A, Prochiantz A. Transduction peptides: from technology to physiology [J]. Nat Cell Biol. 2004;6(3):189\u201396.","journal-title":"Nat Cell Biol"},{"issue":"8","key":"6087_CR46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/boc.201300011","volume":"105","author":"S Willier","year":"2013","unstructured":"Willier S, Butt E, Grunewald TG. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biol Cell. 2013;105(8):317\u201333. https:\/\/doi.org\/10.1111\/boc.201300011 .","journal-title":"Biol Cell"},{"issue":"21","key":"6087_CR47","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1101\/gad.9.21.2583","volume":"9","author":"Y Shi","year":"1995","unstructured":"Shi Y, Alin K, Goff SP. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. Genes Dev. 1995 Nov 1;9(21):2583\u201397.","journal-title":"Genes Dev"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6087-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6087-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6087-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T15:26:56Z","timestamp":1664292416000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6087-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6087"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6087-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"16 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiment procedures were approved by the Medical Ethics Committee of Zhongnan Hospital of Wuhan University and met the requirement of Animal Biosafety Level-3 Laboratory of Wuhan University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that there are no conflicts of interest in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"878"}}